A California lawmaker introduced a new bill that would force health insurers to disclose denial rates and explain those denials as anger grows over rising costs and uncovered medical care.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

From low Medi-Cal reimbursement rates to staffing shortages, California's ASCs are navigating several financial, workforce and market challenges impeding success. Beth LaBouyer, executive director of ...